Menu Search Icon

Search

Department of Pathology

Matthew McCord, M.D.


Assistant Professor of Pathology
Associate Program Director, Neuropathology Fellowship

Education:

Med School: University of Florida College of Medicine, 2012-2018
Residency: Northwestern University Feinberg School of Medicine, Anatomic Pathology, 2018-2020
Fellowship: Northwestern University Feinberg School of Medicine, Neuropathology, 2020-2022
Fellowship: Northwestern University Feinberg School of Medicine, Postdoctoral research, 2022-2024

Clinical Area:

Diagnostic neuropathology including surgical neuropathology, autopsy neuropathology, neurodegenerative disease, neuromuscular pathology, and ophthalmic pathology.

 Research:

My research focuses on understanding how brain tumors become resistant to therapy, identifying biomarkers for therapy sensitivity, and testing new therapies.

Publications:

  • Mondia M, Batchala P, Dreicer R, Devitt M, McCord M, Mut M, Sheehan J, Schiff D, Fadul C. Incidental brain metastases from prostate cancer diagnosed with PSMA PET/CT and MRI: A case series and literature review. The prostate. 2025. Mar; 85(9): 841-49. PMC12068031.
  • Mondia M, Hooks R, Maragkos G, Smith V, McCord M, Donahue J, Williams E, Lopes MB, Schiff D, Asthagiri A. Primary diffuse leptomeningeal glioblastoma: a case report and literature review. J neurooncol. 2025. Mar; 172(1): 265-275. PMC11832630.
  • McCord M, Sears T, Wang W, Chaliparambil R, An S, Sarkaria J, James CD, Ruggeri B, Gueble S, Bindra R, Horbinski C. The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma. Neuro-Oncol. 2025. Mar; 27(3): 644-51. PMC11889708.
  • Sears T, Wang W, Drumm M, Unruh D, McCord M, Horbinski C. F3 expression drives sensitivity to the antibody-drug conjugate tisotumab vedotin in glioblastoma. Cancers. 2025. Feb; 17(5): 834. PMC11898980.
  • An S, McCortney K, Walshon J, Leonard K, Wray B, McCord M, DeCuypere M, Horbinski C. Methylation profiling of plasma cell-free DNA in pediatric brain tumor patients. Acta neuropathol. 2024. Aug; 148(1): 29. PMID: 39187719.
  • Thirunavu V, Drumm M, McCord M, Steffens A, Youngblood M, Nandoliya K, Smith H, Walshon J, McCortney K, Magill S, Horbinski C. Optimizing the use of Ki-67 proliferative index as a prognostic biomarker in meningiomas using digital analysis. J neurosurg. 2024. Jul; 5:1-11. PMID: 38968615.
  • Arrieta V, Gould A, Kim K, Habashy K, Dmello C, Vazquez-Cervantes G, Palacin-Aliana I, McManus G, Amidei C, Gomez C, Dhiantravan S, Chen L, Zhang D, Saganty R, Cholak M, Pandey S, McCord M, McCortney K, Castro B, Ward R, Muzzio M, Bouchoux G, Desseaux C, Canney M, Carpentier A, Zhang B, Miska J, Lesniak M, Horbinski C, Lukas R, Stupp R, Lee-Chang C, Sonabend A. Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas. Nat commun. 2024. Jun; 15(1): 4698. PMC11156895.
  • McCord M, Jamshidi P. Targeting the cell cycle to enhance chemotherapy efficacy in glioblastoma. Neuro-Oncol. 2024. Jun; 26(6): 1097-98. PMC11145455.
  • McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, Parker S, Baczkowski J, Jennings L, Walshon J, McCortney K, Galbraith K, Zhang H, Lukas R, Stupp R, Dixit K, Kumthekar P, Heimberger A, Snuderl M, Horbinski C. Variant allelic frequencies of driver mutations identify gliomas with potentially false-negative MGMT promoter methylation results. Acta neuropathol commun. 2023. Nov; 11(1): 175. PMC10623846.
  • Jamshidi P, McCord M, Galbraith K, Santana-Santos L, Jennings L, Snuderl M, Horbinski C. Variant allelic frequency of driver mutations predicts success of genomic DNA methylation classification in central nervous system tumors. Acta neuropathologica. 2023. Mar; 145(3):365-67. PMC11096842.
  • Reish N, Jamshidi P, Stamm B, Flanagan M, Sugg E, Tang M, Donohue K, McCord M, Krumpelman C, Mesulam M, Castellani R, Chou S. Multiple cerebral hemorrhages in a patient receiving lecanemab treated with t-PA for stroke. N Engl J Med. 2023. Feb; 388(5): 478-79. PMC10228637.
  • McCord M, Bartom E, Burdett K, Baran A, Eckerdt F, Balyasnikova I, McCortney K, Sears T, Cheng S, Sarkaria JN, Stupp R, Heimberger AB, Ahmed A, James CD, Horbinski C. Modeling therapy-driven evolution of glioblastoma with patient-derived xenografts. Cancers. 2022. Nov; 14(22): 5494. PMC9688760.
  • Arrieta V, Chen A, Kane J, Kang S, Kassab C, Dmello C, Zhao J, Burdett K, Upadhyayula P, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks J, Laffleur B, Amidei C, Bruce J, Lukas R, Yamaguchi J, Cieremans D, Rothschild G, Basu U, McCord M, Brat D, Zhang H, Cooper L, Stupp R, Heimberger A, Horbinski C, Iwamoto F, Rabadan R, Sonabend M. ERK 1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature cancer. 2021. Nov; 2: 1372-86. PMC8818262.
  • McCord M, Lukas R, Amidei C, Demars N, Gelb A, Buck J, Sachdev S, Feldman A, Tate M, Dixit K, Brat D, Jennings , Horbinski C. Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. Neuro-Oncology Advances. 2021. Jan-Dec; 3(1). PMC82637.
  • McCord M, Steffens A, Javier R, Kam KL, McCortney K, Horbinski C. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. Acta neuropathologica communications. 2020. Feb 12; 8(1): 15. PMC7017562.
  • Drumm M, Dixit K, Grimm S, Kumthekar P, Lukas R, Raizer J, Stupp R, Chheda M, Kam KL, McCord M, Sachdev S, Kruser T, Steffens A, Javier R, McCortney K, Horbinski C. Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-Oncology. 2020. Apr 15; 22(4): 470-79. PMC7158646.
  • McCord M, Mukouyama Y, Gilbert MR, Jackson S. Targeting WNT signaling for multifaceted glioblastoma therapy. Frontiers in cellular neuroscience. 2017. Oct; 11(318): 1-10. PMC5645527
In This Section down-arrow
Menu